
T. Schneider / Shutterstock.com
17 April 2025NewsBig PharmaLiz Hockley
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
Massachusetts lawsuit claims subsidiary of UK pharma company unlawfully re-patented eculizumab, resulting in overpayments of more than $2 billion.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Big Pharma
10 April 2025 Decision overturns earlier decision allowing generic drug maker to launch version | Dispute centres on $300-million dollar treatment for diabetes, chronic heart failure and kidney disease—currently protected by a challenged SPC.
Editor's picks
Editor's picks
Big Pharma
10 April 2025 Decision overturns earlier decision allowing generic drug maker to launch version | Dispute centres on $300-million dollar treatment for diabetes, chronic heart failure and kidney disease—currently protected by a challenged SPC.
Big Pharma
10 April 2025 Decision overturns earlier decision allowing generic drug maker to launch version | Dispute centres on $300-million dollar treatment for diabetes, chronic heart failure and kidney disease—currently protected by a challenged SPC.